BACKGROUND Carbapenem antibiotics are a pivotal solution for severe infections,particularly in hospital settings.The emergence of carbapenem-resistant bacteria owing to the irrational and extensive use of carbapenems ...BACKGROUND Carbapenem antibiotics are a pivotal solution for severe infections,particularly in hospital settings.The emergence of carbapenem-resistant bacteria owing to the irrational and extensive use of carbapenems underscores the need for meticulous management and rational use.Clinical pharmacists,with their specialized training and extensive knowledge,play a substantial role in ensuring the judicious use of carbapenem.This study aimed to elucidate the patterns of carbapenem use and shed light on the integral role played by clinical pharmacists in managing and promoting the rational use of carbapenem antibiotics at Wenzhou Integrated Traditional Chinese and Western Medicine Hospital.AIM To analyze carbapenem use patterns in our hospital and role of clinical pharmacists in managing and promoting their rational use.METHODS We performed a retrospective analysis of carbapenem use at our hospital between January 2019 and December 2021.Several key indicators,including the drug utilization index,defined daily doses(DDDs),proportion of antimicrobial drug costs to total hospitalization expenses,antibiotic utilization density,and utilization rates in different clinical departments were comprehensively analyzed.RESULTS Between 2019 and 2021,there was a consistent decline in the consumption and sales of imipenem-cilastatin sodium,meropenem(0.3 g),and meropenem(0.5 g).Conversely,the DDDs of imipenem-cilastatin sodium for injection increased in 2020 and 2021 vs 2019,with a B/A value of 0.67,indicating a relatively higher drug cost.The DDDs of meropenem for injection(0.3 g)exhibited an overall upward trend,indicating an increasing clinical preference.However,the B/A values for 2020 and 2021 were both>1,suggesting a relatively lower drug cost.The DDDs of meropenem for injection(0.5 g)demonstrated a progressive increase annually and consistently ranked first,indicating a high clinical preference with a B/A value of 1,signifying good alignment between economic and social benefits.CONCLUSION Carbapenem use in our hospital was generally reasonable with a downward trend in consumption and sales over time.Clinical pharmacists play a pivotal role in promoting appropriate use of carbapenems.展开更多
目的分析近7年大肠埃希菌及肺炎克雷伯菌耐药率与抗菌药物使用强度(antibiotics use density,AUD)的相关性,为临床合理使用抗菌药物提供参考。方法回顾性分析该院2016—2022年大肠埃希菌及肺炎克雷伯菌的耐药率与同期主要抗菌药物的AUD...目的分析近7年大肠埃希菌及肺炎克雷伯菌耐药率与抗菌药物使用强度(antibiotics use density,AUD)的相关性,为临床合理使用抗菌药物提供参考。方法回顾性分析该院2016—2022年大肠埃希菌及肺炎克雷伯菌的耐药率与同期主要抗菌药物的AUD,采用Pearson相关性分析法分析两者的相关性。结果大肠埃希菌对对哌拉西林/他唑巴坦的耐药率与头孢呋辛的AUD呈正相关(P<0.05);对头孢吡肟的耐药率与头孢西丁、氨曲南的AUD呈正相关(P<0.01、P<0.05);对头孢西丁的耐药率与头孢西丁的AUD呈正相关(P<0.05);对亚胺培南的耐药率与头孢哌酮/舒巴坦、阿米卡星的AUD呈正相关(P<0.01)。肺炎克雷伯菌对阿莫西林/克拉维酸的耐药率与头孢西丁、氨曲南的AUD呈正相关(P<0.01);对哌拉西林/他唑巴坦的耐药率与头孢西丁的AUD呈正相关(P<0.05),对头孢噻肟的耐药率与阿莫西林/克拉维酸的AUD呈正相关(P<0.01);对头孢吡肟的耐药率与头孢西丁、左氧氟沙星的AUD呈正相关(P<0.05);对阿米卡星的耐药率与头孢他啶、头孢噻肟、亚胺培南的AUD呈正相关(P<0.01、P<0.05)。大肠埃希菌对哌拉西林/他唑巴坦的耐药率与头孢唑啉的AUD呈负相关(P<0.05);对头孢唑啉的耐药率与头孢他啶、头孢噻肟的AUD呈负相关(P<0.05);对头孢吡肟的耐药率与哌拉西林/他唑巴坦、头孢噻肟的AUD呈负相关(P<0.05);对头孢西丁的耐药率与头孢噻肟的AUD呈负相关(P<0.05);对亚胺培南的耐药率与阿莫西林/克拉维酸的AUD呈负相关(P<0.05)。肺炎克雷伯菌对阿莫西林/克拉维酸的耐药率与哌拉西林/他唑巴坦的AUD呈负相关(P<0.05);对头孢西丁的耐药率与哌拉西林/他唑巴坦的AUD呈负相关(P<0.05)。结论大肠埃希菌及肺炎克雷伯菌的耐药率与多种抗菌药物的AUD相关,应加强抗菌药物的合理管控,延缓细菌耐药的发生。展开更多
文摘BACKGROUND Carbapenem antibiotics are a pivotal solution for severe infections,particularly in hospital settings.The emergence of carbapenem-resistant bacteria owing to the irrational and extensive use of carbapenems underscores the need for meticulous management and rational use.Clinical pharmacists,with their specialized training and extensive knowledge,play a substantial role in ensuring the judicious use of carbapenem.This study aimed to elucidate the patterns of carbapenem use and shed light on the integral role played by clinical pharmacists in managing and promoting the rational use of carbapenem antibiotics at Wenzhou Integrated Traditional Chinese and Western Medicine Hospital.AIM To analyze carbapenem use patterns in our hospital and role of clinical pharmacists in managing and promoting their rational use.METHODS We performed a retrospective analysis of carbapenem use at our hospital between January 2019 and December 2021.Several key indicators,including the drug utilization index,defined daily doses(DDDs),proportion of antimicrobial drug costs to total hospitalization expenses,antibiotic utilization density,and utilization rates in different clinical departments were comprehensively analyzed.RESULTS Between 2019 and 2021,there was a consistent decline in the consumption and sales of imipenem-cilastatin sodium,meropenem(0.3 g),and meropenem(0.5 g).Conversely,the DDDs of imipenem-cilastatin sodium for injection increased in 2020 and 2021 vs 2019,with a B/A value of 0.67,indicating a relatively higher drug cost.The DDDs of meropenem for injection(0.3 g)exhibited an overall upward trend,indicating an increasing clinical preference.However,the B/A values for 2020 and 2021 were both>1,suggesting a relatively lower drug cost.The DDDs of meropenem for injection(0.5 g)demonstrated a progressive increase annually and consistently ranked first,indicating a high clinical preference with a B/A value of 1,signifying good alignment between economic and social benefits.CONCLUSION Carbapenem use in our hospital was generally reasonable with a downward trend in consumption and sales over time.Clinical pharmacists play a pivotal role in promoting appropriate use of carbapenems.
文摘目的分析近7年大肠埃希菌及肺炎克雷伯菌耐药率与抗菌药物使用强度(antibiotics use density,AUD)的相关性,为临床合理使用抗菌药物提供参考。方法回顾性分析该院2016—2022年大肠埃希菌及肺炎克雷伯菌的耐药率与同期主要抗菌药物的AUD,采用Pearson相关性分析法分析两者的相关性。结果大肠埃希菌对对哌拉西林/他唑巴坦的耐药率与头孢呋辛的AUD呈正相关(P<0.05);对头孢吡肟的耐药率与头孢西丁、氨曲南的AUD呈正相关(P<0.01、P<0.05);对头孢西丁的耐药率与头孢西丁的AUD呈正相关(P<0.05);对亚胺培南的耐药率与头孢哌酮/舒巴坦、阿米卡星的AUD呈正相关(P<0.01)。肺炎克雷伯菌对阿莫西林/克拉维酸的耐药率与头孢西丁、氨曲南的AUD呈正相关(P<0.01);对哌拉西林/他唑巴坦的耐药率与头孢西丁的AUD呈正相关(P<0.05),对头孢噻肟的耐药率与阿莫西林/克拉维酸的AUD呈正相关(P<0.01);对头孢吡肟的耐药率与头孢西丁、左氧氟沙星的AUD呈正相关(P<0.05);对阿米卡星的耐药率与头孢他啶、头孢噻肟、亚胺培南的AUD呈正相关(P<0.01、P<0.05)。大肠埃希菌对哌拉西林/他唑巴坦的耐药率与头孢唑啉的AUD呈负相关(P<0.05);对头孢唑啉的耐药率与头孢他啶、头孢噻肟的AUD呈负相关(P<0.05);对头孢吡肟的耐药率与哌拉西林/他唑巴坦、头孢噻肟的AUD呈负相关(P<0.05);对头孢西丁的耐药率与头孢噻肟的AUD呈负相关(P<0.05);对亚胺培南的耐药率与阿莫西林/克拉维酸的AUD呈负相关(P<0.05)。肺炎克雷伯菌对阿莫西林/克拉维酸的耐药率与哌拉西林/他唑巴坦的AUD呈负相关(P<0.05);对头孢西丁的耐药率与哌拉西林/他唑巴坦的AUD呈负相关(P<0.05)。结论大肠埃希菌及肺炎克雷伯菌的耐药率与多种抗菌药物的AUD相关,应加强抗菌药物的合理管控,延缓细菌耐药的发生。
